(August 18, 2017, 10:59 AM EDT) -- WASHINGTON, D.C. — Ten months after Mylan Inc. first announced a settlement and seven months after the federal government said there was no such agreement, Mylan and the U.S. Justice Department on Aug. 17 finalized a $465 million settlement of claims that the EpiPen maker violated the False Claims Act by misclassifying the drug/device combination as generic to avoid paying higher rebates owed primarily to Medicaid (United States, ex rel. Sanofi-Aventis US LLC v. Mylan Inc., No. 16-11572, D. Mass.)....